Patient disposition and baseline characteristics
TEAEs
DISEASE PROGRESSION
Patients were randomly assigned to the lenvatinib 18 mg starting dose arm (As of the data cutoff date (December 12, 2019), 45.5% and 57.3% of patients in the lenvatinib 18 and 24 mg starting‐dose arms, respectively, were still undergoing treatment. Disease progression was the primary reason for discontinuation in 26.0% and 17.3% of patients in the lenvatinib 18 mg and 24 mg starting‐dose arms, respectively; and AEs were the primary reason for discontinuation in 15.6% of patients in the lenvatinib 18 mg starting‐dose arm, and 13.3% of patients in the 24 mg starting dose arm. All TEAEs that resulted in discontinuation of lenvatinib were each reported by no more than one patient in either treatment arm.